Vimarsana
Biggest News Aggregation in the World

Page 2 - Bymark Leiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bymark Leiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bymark Leiser Today - Breaking & Trending Today

Findings highlight need to improve prior authorization process for cancer pain management - Vimarsana News

Findings highlight need to improve prior authorization process for cancer pain management

CHICAGO — A review of more than 1,700 prior authorization requests related to pain medication for people with cancer showed the vast majority ultimately got approved.However, chart reviews documented uncontrolled pain and unmanageable side effects for many patients whose requests had been denied.

Source: healio.com
MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset - Vimarsana News

MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.Patients with MET-positive status appeared five times as likely as those with MET-negative status to respond to amivantamab (Rybrevant, Janssen) plus lazertinib

Source: healio.com
ChatGPT-generated next-generation sequencing reports yield 'promising' recommendations - Vimarsana News

ChatGPT-generated next-generation sequencing reports yield 'promising' recommendations

CHICAGO — ChatGPT can be used to develop next-generation sequencing reports that outline treatment strategies for patients who have non-small cell lung cancer with driver oncogenes, according to results presented at ASCO Annual Meeting.Investigators from University of Illinois Cancer Center characterized the recommendation relevance as moderate and accuracy as limited (46%, 95% CI,

Source: healio.com
Tumor-treating fields extend OS in metastatic NSCLC - Vimarsana News

Tumor-treating fields extend OS in metastatic NSCLC

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting. Researchers observed no exacerbation in systemic toxicities and reported few high-grade device-related toxicities, results of the

Source: healio.com
KEYNOTE-716: Primary melanoma, not lymph nodes, should 'drive therapeutic decision-making' - Vimarsana News

KEYNOTE-716: Primary melanoma, not lymph nodes, should 'drive therapeutic decision-making'

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial

Source: healio.com